Alzamend Neuro Files 8-K on Agreements and Equity Sales

Ticker: ALZN · Form: 8-K · Filed: Feb 28, 2025 · CIK: 1677077

Alzamend Neuro, INC. 8-K Filing Summary
FieldDetail
CompanyAlzamend Neuro, INC. (ALZN)
Form Type8-K
Filed DateFeb 28, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-filing

Related Tickers: ALZN

TL;DR

Alzamend Neuro (ALZN) filed an 8-K detailing new deals and stock sales.

AI Summary

Alzamend Neuro, Inc. filed an 8-K on February 28, 2025, reporting on the entry into a material definitive agreement, unregistered sales of equity securities, and financial statements. The filing details the company's corporate structure and business address in Atlanta, GA.

Why It Matters

This filing provides crucial updates on Alzamend Neuro's material agreements and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can indicate significant corporate actions and potential dilution.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement mentioned in the filing?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.

What type of equity securities were sold unregistered?

The filing states 'Unregistered Sales of Equity Securities' as an item information, but the specific type and details of these securities are not elaborated in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 28, 2025.

Where is Alzamend Neuro, Inc. headquartered?

Alzamend Neuro, Inc.'s principal business address is located at 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326.

What is the SIC code for Alzamend Neuro, Inc.?

The Standard Industrial Classification (SIC) code for Alzamend Neuro, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 regarding Alzamend Neuro, Inc. (ALZN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing